Design Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $665.06M
- P/E (TTM)
- –
- Dividend yield
- –
About Design Therapeutics
Pharmaceutical Preparations, SIC 2834
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutic candidates called GeneTAC molecules. These chimera molecules are designed to treat monogenic degenerative diseases caused by inherited nucleotide repeat expansion mutations, which lead to either protein deficiencies or toxic gene products. The company's lead investigational programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and an early-stage research program targeting Huntington's disease. As a clinical-stage entity, the company primarily serves patient populations with these genetic conditions through clinical development and trials.
The company operates in a single operating segment focused on the development of its therapeutic platform and product pipeline. Its clinical trials and nonclinical studies evaluate candidates across multiple indications, including ongoing clinical development in the United States. Design Therapeutics maintains its principal executive offices and headquarters in Carlsbad, California.
Summary of the business section of Design Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Design Therapeutics, Inc.
- Headquarters
- Carlsbad, CA
- Address
- 6005 Hidden Valley Road, Suite 110 92011
- Phone
- (858) 293-4900
- Website
- designtx.com
- Employees
- 54, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- DSGN
- Exchange
- Nasdaq
- IPO date
- Mar 26, 2021
- Shares outstanding
- 63M, Jul 29, 2026
- Public float
- $114.34M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1807120
- CUSIP
- 25056L103
- ISIN
- US25056L1035
- EIN
- 82-3929248
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Pratik Shah | President, CEO and Chairperson, Director | 154,923 |
| Julie Burgess | Chief Accounting Officer | – |
| Chris Storgard | Chief Medical Officer | – |
| Sean Jeffries | Chief Operating Officer | 810,283 |
| Simeon George | Director | 6,526,476 |
| John P. Schmid | Director | 57,639 |
| David Shapiro | Director | – |
| Rodney W. Lappe | Director | 133,024 |
| Heather A. Berger | Director | 1,300 |
| Justin D. Gover | Director | – |
| Arsani William | Director | 3,655,000 |
| Deepa Prasad | Director | 1,837,273 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 54 employees, all of whom were full-time, and 20 of whom have a Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 26, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |